Kuros Biosciences received FDA 510(k) clearance to extend its MagnetOs Putty indications to use as a standalone bone graft in the extremities and pelvis.

Kuros Biosciences' MagnetOs is a suitable alternative to autograft for spinal fusion when used as a standalone graft, according to an animal study in JOR Spine.

Carmell Therapeutics is a biotechnology company focused on plasma-based bioactive materials.

The global spinal biologics market is predicted to grow at a 3.75 percent compound annual growth rate, reaching $2.36 billion by 2021, according to a Research Cosmos report.

Anika Therapeutics resumed distribution of its solid hyaluronic acid-based treatments after a voluntary, non-safety related recall in the second quarter.

AlloSource received a U.S. patent for its proprietary method to create ProChondrixCR, the company's fresh cryopreserved osteochondral allograft.  

Bio2 Technologies is an orthobiologics company.

The global spine biologics market is projected to grow at a 3.5 percent compound annual growth rate to reach $2.72 billion by the end of 2025, according to a Market Reports World report.

Grand Junction, Colo.-based Vail-Summit Orthopaedics & Neurosurgery is using injectable plasma and stem cells to treat sports-related ligament and tendon injuries, according to an article written by William Sterett, MD, in Summit Daily.

Regenerative medicine company Osiris Therapeutics named Samson Tom as president and CEO.

SpinalCyte received FDA Investigational New Drug clearance for CybroCell, its fibroblast-based therapy to treat degenerative disc disease.

Researchers implanted tissue-engineered spinal discs in a goat model which provided long-term function, according to a study in Science Translational Medicine.

Stability Biologics provides allograft products for spine, orthopedic and wound care applications.

Researchers have developed a composite double-network hydrogel that adheres to soft tissues such as cartilage and the meniscus, according to an article in ACS Applied Materials & Interfaces.

SurGenTec completed the initial clinical launch of its new GraftGun bone graft delivery system combined with Aziyo Biologics’ ViBone Viable Bone Matrix prefilled tubes for minimally invasive spine surgery. 

ORTHOReBIRTH USA and Altamonte Springs, Fla.-based Adventist Health System Sunbelt Healthcare Corp. entered into a product agreement.

Spinal device company Innovasis partnered with Stability Biologics to enter the biologics market.

The FDA warned StemGenex Biologic Laboratories about illegally marketing an unapproved stem cell product produced in a facility with significant manufacturing violations, putting patients at risk.

CollPlant is a regenerative medicine company focused on 3D bioprinting tissues and organs and developing orthobiologics.

SpinalCyte reported positive 12-month endpoint MRI outcomes in a clinical study of its CybroCell injection for degenerative disc disease.